Phase 4Recruiting
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (MESSAGE)
Efficacy and Safety of the Triple Combination Therapy of Met/SGLT-2i/GLP-1RA or Other Oral Antidiabetic Drugs in Patients With Type 2 Diabetes Exhibiting Poor Glycemic Control
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Industry)
- Enrolment
- 430 planned
- Conditions
- T2DM (Type 2 Diabetes Mellitus)
- Interventions
- Metformin; Triple Therapy of Other Oral Antidiabetic Drugs; ganagliflozin; liraglutide
- Ages
- adults, older adults
- Registry
- NCT07244003
Full record on ClinicalTrials.gov
From the registry
The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.
Primary outcomes
- The change of HbA1c compared to the baseline
History
Study completion expected
Primary completion expected
Registered
Started